Last updated: June 8, 2026
Doxorubicin hydrochloride (liposomal) is supplied in the US primarily as pegylated liposomal doxorubicin (PLD) under branded products. Supplier landscape is dominated by the branded manufacturers that hold the marketed product supply chain and the contract manufacturing organizations (CMOs) that produce liposome drug substance and drug product under controlled technology transfer.
Which companies supply liposomal doxorubicin (doxorubicin hydrochloride) to the market?
Pegylated liposomal doxorubicin (PLD): what is the dominant US supply channel?
In the US, the core commercial product is pegylated liposomal doxorubicin. The market is supplied by:
- Janssen Biotech, Inc. (via Janssen’s branded supply chain for PLD products marketed in the US)
- Accord/other branded generics using a different label only if an FDA-approved PLD product is available under the same active ingredient and dosage form
The practical procurement answer for commercial transactions is: buy through the brand manufacturer distribution network unless your purchasing is set up for an FDA-approved non-brand equivalent product and you have locked the specific NDC, strength, and presentation.
What dosage forms matter for supplier selection?
Supplier capability depends on the exact presentation:
- Single-dose vials for IV infusion
- Ready-to-infuse or concentrate configurations depending on label
For liposomal doxorubicin, procurement teams typically tie supply to:
- NDC and vial strength
- Manufacturing batch-release constraints
- Storage and cold-chain handling requirements stated on labeling
What contract manufacturers (CMOs) make liposomal doxorubicin for the branded supply chain?
How to identify CMO involvement in liposomal oncology product manufacturing
For liposomal doxorubicin, CMO involvement is common for:
- Liposome drug substance (lipid mixing, ethanol removal, sterile filtration steps where applicable)
- Drug product fill-finish (aseptic fill into vials, lyophilization or sterile liquid fill depending on the product)
- Analytical release (encapsulation efficiency, particle sizing, residual solvent limits, sterility, endotoxin)
Under typical branded programs, CMOs are selected through:
- Technology transfer agreements
- QA release ownership and batch record control
- Stability program support
Procurement due diligence should verify:
- Which site releases the final batch
- Whether the CMO produces the liposome under proprietary lipid composition and manufacturing know-how
- Whether the CMOs are responsible for ongoing comparability during process changes
Where do suppliers come from: global manufacturing sites and US distribution partners?
Global supply chain topology for liposomal doxorubicin
Liposomal doxorubicin supply is usually structured as:
- Active liposome manufacturing at designated GMP sites
- Drug product manufacturing at GMP fill-finish sites
- US release testing and distribution through the brand’s primary wholesaler network
Procurement risk is concentrated in:
- One or two key GMP release sites
- Bottlenecks tied to sterile fill-finish capacity
- Lipid raw material sourcing and QC acceptance
What raw materials and key inputs constrain supply of liposomal doxorubicin?
Inputs that can create shortages
Liposomal oncology products are sensitive to:
- Lipid components (PEG-lipids and phospholipids)
- Buffers and pH adjustment components
- Sterile filtration supplies and aseptic consumables
- Analytical reference standards
- Primary packaging components (vials, stoppers, seals)
The most common supplier failure modes in liposomal formulations are:
- Raw material lot rejection due to specification drift
- QC release delays for lipid intermediates
- Aseptic fill-finish queue constraints
What procurement strategies reduce risk for liposomal doxorubicin supply?
Commercial purchasing playbook
A procurement team typically reduces exposure by:
- Locking orders to specific lot-release dates and minimum shelf-life at receipt
- Using dual-source options only if there is an FDA-approved alternative presentation with equivalent clinical attributes
- Pre-qualifying warehouses for labeling-compliant storage conditions
- Including lead-time buffers tied to batch release schedules
Contracting terms that matter
For liposomal IV oncology products, supply agreements should address:
- Allocation logic during constrained supply
- Change control notifications for manufacturing site or process adjustments
- Guaranteed fill frequency and replacement terms for out-of-spec batch investigations
How many FDA-approved suppliers exist for liposomal doxorubicin in the US?
Supplier count depends on FDA approvals and label
The number of suppliers is not equivalent to the number of manufacturers. It is driven by:
- Whether multiple NDAs/ANDAs exist for the same dosage form and strength
- Whether an alternative product is actually interchangeable at the presentation level
In procurement terms:
- If only one branded PLD product is marketed in your target NDC strength, supplier count is essentially 1
- If multiple FDA-approved equivalents exist for the same indication and administration format, you can broaden to 2+ suppliers, still limited by NDC-specific supply
What supplier options exist if you need an alternative to branded pegylated liposomal doxorubicin?
Non-brand PLD products and importation
Where FDA-approved non-brand versions exist, they may be sourced through:
- US generic manufacturers with their own distribution
- Importers, if the product is approved and distributed under US labeling
Key procurement gates:
- NDC and vial strength matching
- Patient dosing equivalence and infusion protocol as labeled
- Supply stability in your contracting window
Key Takeaways
- Doxorubicin hydrochloride (liposomal) supply in the US is dominated by pegylated liposomal doxorubicin brands with controlled distribution networks.
- Supplier risk for liposomal doxorubicin is driven by sterile manufacturing capacity, lipid raw material sourcing, and batch release bottlenecks.
- Procurement should be NDC-lot-specific and contractually anchored to allocation and replacement terms.
- Secondary supplier options exist only when there are FDA-approved alternative products in the same dosage form, strength, and presentation; otherwise the effective supplier base remains brand-led.
FAQs
1) Who distributes pegylated liposomal doxorubicin (PLD) in the US?
Brand-led distribution through the product’s authorized wholesale network is the default route, with distribution controlled by the marketed product holder’s supply chain.
2) What is the biggest supply bottleneck for liposomal doxorubicin?
Aseptic fill-finish capacity and batch-release testing for sterile liposomal products, plus constrained lipid input sourcing.
3) Can I qualify multiple suppliers for liposomal doxorubicin without changing clinical protocol?
Only if the suppliers offer an FDA-approved product with matching NDC strength and equivalent labeled administration attributes.
4) What contract terms matter most when buying liposomal oncology drugs under allocation?
Lot-based ordering windows, allocation rules, substitution limits, and replacement terms for batch-related quality events.
5) How should storage and handling requirements be handled in procurement contracts?
Align receipt conditions to labeling, specify responsibility for excursions, and require documentation of storage compliance through transit and warehousing.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Shortages. FDA.
- FDA. Product labeling for pegylated liposomal doxorubicin (liposomal doxorubicin hydrochloride) including prescribing information and storage/handling instructions.
